Better Therapeutics and Glooko team to to integrate AspyreRx to treat T2D

Better Therapeutics and Glooko announced a partnership to integrate Better Therapeutics’ AspyreRx digital behavioral treatment for type 2 diabetes, T2D, into Glooko’s diabetes management platform. This collaboration will enable healthcare providers in the United States who use the Glooko platform to identify suitable patients for AspyreRx, facilitate prescriptions, and track patients throughout their treatment. “We are very pleased to partner with Better Therapeutics to add AspyreRx to the Glooko platform,” stated Russ Johannesson, CEO of Glooko. “This partnership will facilitate access to an important new treatment option for healthcare providers in the Glooko network, enabling them to better manage their patient populations and enhance health outcomes for patients with T2D.”